Key facts
- This page summarizes Michael Vasconcelles's Form 4 filing for ImmunoGen, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 03 Jan 2023, 16:17.
Michael Vasconcelles - 29 Dec 2022 Form 4 Insider Report for ImmunoGen, Inc.
- Signature
- /s/ Renee Lentini, Attorney-in-Fact
- Issuer symbol
- N/A
- Transactions as of
- 29 Dec 2022
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 03 Jan 2023, 16:17:11 UTC
- Previous filing
- 17 Aug 2022
- Next filing
- 03 Jan 2024
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Michael Vasconcelles filed Form 4 for ImmunoGen, Inc. on 03 Jan 2023.
Change
- Previous filing in this sequence was filed on 17 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
IMGN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +960,000
- Change %
- Price
- $0.000000
- Shares after
- 960,000
- Date
- 29 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 960,000
- Exercise price
- $5.16
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. |